Extended Data Fig. 9: Demographic information on human samples used in the study. | Nature Aging

Extended Data Fig. 9: Demographic information on human samples used in the study.

From: A blood-based DNA damage signature in patients with Parkinson’s disease is associated with disease progression

Extended Data Fig. 9

a) Table summarizing the characteristics iPD patients and healthy controls used in the analysis of DNA damage markers in PBMC; (b, e) Heatmaps originated with FUMA analysis from (b, c) up- and (d, e) downregulated genes highlighting sets of genes related to brain regions. (f) list of up- and downregulated genes inferred from FUMA heatmaps that are related to brain regions. (g) Table describing the characteristics of the Queen Square Brain Bank (QSBB) post-mortem substantia nigra pars compacta specimens (Add path: additional diagnosed pathologies, none of which were reported; Braak tau: Braak staging based on tau pathology; Thal phase: diffuse Aβ plaque burden; CERAD: Consortium to Establish a Registry for Alzheimer’s Disease score; ABC: tiered evaluation for 3 diffuse Aβ plaque and NFT burden, and neuritic plaque location and density based on CERAD score; alpha-syn Braak: Braak staging based on alpha-synuclein pathology; McKeith: McKeith consensus criteria for dementia with Lewy bodies diagnosis).

Back to article page